L'intérêt à découvert pour Rapport Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Rapport Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Rapport Therapeutics (NASDAQ:RAPP) Stock, Rapport sur les intérêts à découvert

Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics Inc

Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) analysts raised their price targets on the stock and questioned why shares were falling Friday after reporting better-than-expected <a href="https://www.benzinga.com/markets/earnings/25/07/46774978/amazon-q2-earnings-highlights-double-beat-ai-progress-across-the-board-continues">second-quarter results</a>.
<ul class="wp-block-list">
<li>Bank of America analyst Justin Post reiterated a Buy rating and raised the price target from $265 to $272.</li>
<li>RBC Capital analyst Brad Erickson maintained an Outperform rating and raised the price target from $230 to $240.</li>
<li>Canaccord Genuity analyst Maria Ripps maintained a Buy rating with a price target of $280.</li>
<li>Needham analyst Laura Martin maintained a Buy rating with a price target of $265.</li>
<li>Rosenblatt analyst Barton Crockett maintained a Buy rating and raised the price target from $288 to $297.</li>
<li>Telsey analyst Joseph Feldman maintained an Outperform rating and raised the price target from $235 to $265.</li>
<li>Goldman Sachs analyst Eric Sheridan reiterated a Buy rating and raised the price target from $220 to $240.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/tech/25/08/46782730/amazon-stock-tanks-as-aws-misses-whisper-number-i-dont-know-whats-wrong-with-it-says-gene-munster">Amazon Stock Tanks As AWS Misses Whisper Number: &#8216;I Don&#8217;t Know What&#8217;s Wrong With It,&#8217; Says Gene Munster</a>
Bank of America: The e-commerce giant's retail segment drove upside in the quarter. AWS, however, reported a mixed result, Post said in a new investor note.
"While AWS lost ground for revenues in 2Q, deal signings were strong and Amazon is still capacity constrained," Post said.
The analyst said it's "still very early' for the AI Cloud segment, with expected acceleration for Amazon.
Outside of AWS, the analyst said the retail segment is benefiting from a focus on speed and efficiency improvements.
RBC Capital: Erickson asks if Amazon has structural issues, or if this was just an off night for the company.
"AMZN had a mixed print and an even tougher conference call," Erickson said in an investor note.
The retail business is firing on "most if not all cylinders," he added. But AWS growth didn't accelerate like Amazon's peers in the markets.
"Margins missed and management's commentary on the call did little to attenuate investor fears that AWS may have a bigger structural issue in capturing its fair share of the growth from AI."
The analyst said they are confident in Amazon being able to accelerate AWS growth over time and the company restoring investor faith in the AI opportunity.
Canaccord Genuity: Amazon's retail segment was the highlight in the quarter for Ripps.
"Online stores revenue growing in the double-digits for the first time since 2Q21, in part reflecting ongoing momentum with Everyday Essentials," Ripps said.
The analyst also highlighted Amazon management commentary that demand has not been weakened due to tariffs or price increases.
While AWS garnered most of the headlines, Ripps said Amazon looks strong, with growth in Online stores and third-party seller services, as well as the company's focus on delivery speeds and a 20%+ year-over-year growth in advertising.
Needham: Martin says weak AWS results, lower than expected guidance and higher CapEx spending overshadow a strong quarter.
"What investors are most worried about are weak AWS margins," Martin said, citing 33% in the second quarter and 39% in the first quarter.
Amazon, as a service company, deserves a higher multiple than being labeled a products company, she added. The analyst notes that Amazon's Services revenue have been higher than its product revenue in the past 13 quarters.
The analyst lays out a sum-of-the-parts valuation for Amazon that is as follows:
<ul class="wp-block-list">
<li>Subscription businesses: $323.6 billion</li>
<li>Advertising revenue: $668.7 billion</li>
<li>AWS Assets: $1.02 trillion</li>
<li>Other Revs: $6 billion</li>
</ul>
Based on this valuation, Amazon's e-commerce business is worth $613 billion, or 1.3 times the estimated 2025 revenue for the segment, which Martin calls inexpensive.
"We are buyers of AMZN on weakness."
Rosenblatt: The weaker-than-expected growth for AWS comes with strong demand and a long runway, Crockett said.
"AWS failed to share in the accelerating growth of smaller rivals Microsoft Azure and Google Cloud," Crockett said." But AI-driven cloud compute is a marathon, not a sprint, and we still expect Amazon to run a solid race in that sector."
The analyst sees a focus on productivity, margin strength, and strong advertising growth as helping to offset some of the AWS concerns.
Telsey: All three of Amazon&#8217;s main segments are seeing sales growth and strong profits, Feldman said.
"We were encouraged to see sequential sales acceleration across all three segments," he added.
The analyst highlighted Amazon's product assortment and its focus on the high-growth category of everyday essentials.
"Amazon should continue to gain market share by leveraging its sticky Prime member base, small business relationships, and technological edge."
Goldman Sachs: While e-commerce growth and margins were strong, the Amazon debate going forward will be on AWS, Sheridan said in a new investor note.
Sheridan said the scaling of AI and non-AI workloads is likely to be the biggest drivers of investor sentiment going forward.
The analyst said AWS and tariffs are likely to remain key concerns for investors.
"We see AMZN as well-positioned for future outperformance," Sheridan said.
AMZN Price Action: Amazon stock is down 7.8% to $215.83 on Friday versus a 52-week trading range of $151.61 to $242.52. Amazon stock is now down 2.0% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46697035/amazon-denies-raising-prices-due-to-trump-tariffs-consistently-offering-customers-low-prices-every-day">Amazon Denies Raising Prices Due To Trump &amp; Tariffs: &#8216;Consistently Offering Customers Low Prices Every Day&#8217;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

AMZN

Amazon Stock Hit On AWS: Analysts Brush Off Growth Concerns, 'Buyers Of AMZN On Weakness'

BMO Capital analyst Jeffrey Silber maintains Strategic Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRA#NASDAQ">STRA</a>) with a Outperform and lowers the price target from $98 to $88.

News

STRA

BMO Capital Maintains Outperform on Strategic Education, Lowers Price Target to $88

<h3>Gainers</h3>
<ul>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares moved upwards by 175.9% to $0.99 during Friday's regular session. The company's market cap stands at $4.2 million. </li>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) stock moved upwards by 27.86% to $2.71. The company's market cap stands at $2.4 million. </li>
<li>Cooper-Standard Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPS#NYSE">CPS</a>) stock rose 15.6% to $27.86. The company's market cap stands at $422.9 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Aureus Greenway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock increased by 12.09% to $2.78. The company's market cap stands at $34.4 million. </li>
<li>Johnson Outdoors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOUT#NASDAQ">JOUT</a>) stock increased by 11.02% to $36.86. The company's market cap stands at $342.8 million. The company's, Q3 earnings came out today. </li>
<li>Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) stock increased by 9.84% to $124.24. The company's market cap stands at $6.4 billion. The company's, Q2 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) shares decreased by 18.8% to $1.1 during Friday's regular session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Sunlands Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STG#NYSE">STG</a>) shares declined by 16.8% to $7.66. The company's market cap stands at $124.4 million. </li>
<li>Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) stock decreased by 16.58% to $4.68. The market value of their outstanding shares is at $2.3 billion. The company's, Q2 earnings came out today. </li>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) stock decreased by 15.9% to $53.65. The market value of their outstanding shares is at $1.2 billion. </li>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) shares declined by 14.43% to $3.21. The company's market cap stands at $763.3 million. As per the news, the Q2 earnings report came out 2 days ago. </li>
<li>Leggett &amp; Platt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) shares decreased by 14.25% to $8.19. The company's market cap stands at $1.2 billion. As per the news, the Q2 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BFAM

JOUT

LOBO

LVWR

LXEH

NEGG

XELB

12 Consumer Discretionary Stocks Moving In Friday's Intraday Session

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/08/2025-08-01_08h51_46.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Raise Cash And Hedges</h4>
it is time to raise hedges. 
<h4 class="wp-block-heading">A Negative Pattern</h4>
Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (QQQ).
Note the following:
<ul class="wp-block-list">
<li>The chart shows a prolonged run.</li>
<li>The chart shows an outside day after the prolonged run.&nbsp; This is a negative pattern.</li>
<li>The chart shows slightly higher volume.&nbsp; This is quasi-confirmation of the negative pattern. A heavier volume would have been better confirmation.</li>
<li>RSI shown on the chart is approaching the oversold level.&nbsp; This indicates there could be a bounce.</li>
<li>The chart shows the major support level at zone 1.</li>
<li>The chart shows that QQQ is levitating considerably above the major support zone. This illustrates the risk.&nbsp; Smart money pays attention to both risk and reward.&nbsp; In contrast, the momo crowd has stars in their eyes and ignores risk.</li>
<li>Figma Ord Shs (FIG) is a new IPO that was priced at $33.  It has traded as high as $147.87 as of this writing in the premarket.  No, Figma did not cure cancer; Figma is a cloud based platform where teams design, prototypes, and collaborate on digital products in real time.  FIG stock is now valued at over 70 times sales (not earnings).  Buying is coming mostly from the momo crowd. Figmazation of the momo crowd should ring alarm bells for investors as it is indicating extreme exuberance.  As we have been sharing with you, extreme positive sentiment is a contrary indicator.  In plain English, it means caution.  It is worth a reminder that sentiment is not a precise timing indicator.  </li>
<li>There is unease in the markets due to two actions from President Trump: 
<ul class="wp-block-list">
<li>President Trump has imposed sweeping tariffs on countries that have not yet reached a deal.  The most notable are high tariffs of 39% on Switzerland and 35% on Canada.</li>
<li>President Trump is making it clear that tariffs are not only about economics.&nbsp; Countries must toe President Trump's geopolitical line lock, stop, and barrel or be met with harsh treatment.&nbsp;&nbsp; 
<ul class="wp-block-list">
<li>Tariffs on Taiwan are raising concern that President Trump will not support Taiwan in the event of a Chinese invasion.</li>
<li>Tariffs on India are raising a concern that President Trump is walking away from an alliance with the world's largest democracy to counter China.&nbsp; Further, President Trump is weaponizing Pakistan, India's archrival and close ally of China, against India.&nbsp;&nbsp;</li>
</ul>
</li>
<li>The foregoing has serious negative implications in the long term for prudent investors in the U.S. markets.&nbsp;&nbsp;</li>
</ul>
</li>
<li>Prudent investors should note the long term negative implications for investors of the only country exempt from President Trump's harsh treatment with tariffs is China.  China is the main strategic rival of the U.S.  During his campaign and up until about two months ago, the main target of President Trump's fire was China.  In our analysis, this was highly justified and badly needed because of the massive transfer of wealth from the U.S. to China over the last 25 years.  However, China has turned the tables as China has the U.S. over a barrel on rare earth minerals.</li>
<li>The jobs report was weak.&nbsp; The weak jobs report is adding fuel to President Trump's attacks on Fed Chair Powell.&nbsp; Here are the details: 
<ul class="wp-block-list">
<li>Non-farm payrolls came at 73K vs. 102K consensus.</li>
<li>Non-farm private payrolls came at 83K vs. 110K consensus.</li>
<li>Unemployment rate came at 4.2%% vs. 4.2% consensus.</li>
<li>Average work week came at 34.3 vs. 34.2 consensus.</li>
<li>Average hourly earnings came at 0.3% vs. 0.3% consensus.</li>
</ul>
</li>
<li>In addition to the current data, there are big downward revisions to the data for the last two months.&nbsp; Prudent investors should pay attention that the economic data appears to be less accurate now and more prone to revisions due to staff cuts in the U.S. government.&nbsp; If the accuracy of that data continues to worsen, it will make the markets more volatile.</li>
<li>Expect blind money to flow into the stock market today.&nbsp; Blind money is the money that flows into the stock market on the first two days of the month without any analysis irrespective of market conditions.</li>
<li>ISM Manufacturing Index and University of Michigan Consumer Sentiment was released at 10am ET today.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Apple Inc (AAPL).
In the early trade, money flows are neutral in Microsoft Corp (MSFT).
In the early trade, money flows are negative in Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), NVIDIA Corp (NVDA), and Tesla Inc (TSLA).
In the early trade, money flows are negative in SPDR S&amp;P 500 ETF Trust (SPY) and Nasdaq 100 ETF (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">What To Do Now</h4>
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Market Summary

Opinion

Markets

Tech Stocks Trace A Negative Pattern; Figmazation Of Momo Crowd; Trump Weaponizes Tariffs

<h3>Gainers</h3>
<ul>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) stock rose 115.6% to $7.66 during Friday's regular session. The market value of their outstanding shares is at $277.9 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) stock increased by 58.82% to $1.62. The company's market cap stands at $7.7 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares increased by 34.96% to $0.53. The company's market cap stands at $13.9 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares increased by 29.25% to $9.67. The market value of their outstanding shares is at $9.4 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock increased by 27.61% to $2.56. The market value of their outstanding shares is at $162.5 million. </li>
<li>Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) shares increased by 26.84% to $13.42. The company's market cap stands at $1.5 billion. As per the press release, Q2 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares fell 38.6% to $1.37 during Friday's regular session. The market value of their outstanding shares is at $67.4 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares declined by 37.62% to $9.32. The market value of their outstanding shares is at $8.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 29.33% to $3.56. The market value of their outstanding shares is at $3.5 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 21.93% to $1.33. The market value of their outstanding shares is at $6.5 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares decreased by 19.77% to $2.76. The company's market cap stands at $48.0 million. </li>
<li>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) shares declined by 17.01% to $2.54. The company's market cap stands at $117.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATEC

CALC

IMAB

MYNZ

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

PHLT

SLXN

SNSE

TNON

ZYXI

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Marwynn Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) stock moved upwards by 46.7% to $1.32 during Friday's regular session. The company's market cap stands at $15.3 million. </li>
<li>Erayak Power Solution Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAYA#NASDAQ">RAYA</a>) stock moved upwards by 35.69% to $0.08. The company's market cap stands at $2.6 million. </li>
<li>Interface (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares rose 16.92% to $24.11. The market value of their outstanding shares is at $1.2 billion. As per the news, the Q2 earnings report came out today. </li>
<li>Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) shares rose 16.23% to $505.0. As per the news, the Q2 earnings report came out 2 days ago. </li>
<li>Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) shares increased by 12.93% to $11.0. The market value of their outstanding shares is at $185.6 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Rich Sparkle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANPA#NASDAQ">ANPA</a>) shares rose 12.28% to $31.0. The company's market cap stands at $345.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares declined by 54.7% to $0.26 during Friday's regular session. The market value of their outstanding shares is at $6.9 million. </li>
<li>TTEC Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEC#NASDAQ">TTEC</a>) shares decreased by 36.75% to $3.15. The company's market cap stands at $238.2 million. </li>
<li>Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) shares decreased by 29.5% to $40.02. The company's market cap stands at $9.3 billion. The company's, Q2 earnings came out today. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) shares declined by 25.15% to $0.18. The market value of their outstanding shares is at $35.5 million. </li>
<li>Insperity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) stock decreased by 22.8% to $46.0. The market value of their outstanding shares is at $2.2 billion. As per the press release, Q2 earnings came out today. </li>
<li>Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) stock fell 20.53% to $10.65. The company's market cap stands at $2.5 billion. As per the news, the Q2 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANPA

ENVX

FORR

MWYN

RAYA

SCWO

SGBX

TILE

TTEC

12 Industrials Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Workiva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WK#NYSE">WK</a>) shares rose 25.8% to $80.28 during Friday's regular session. The company's market cap stands at $3.5 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Mega Fortune Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRT#NASDAQ">MGRT</a>) stock rose 21.13% to $2.98. The market value of their outstanding shares is at $33.8 million. </li>
<li>Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) stock moved upwards by 16.6% to $3.37. The company's market cap stands at $8.1 million. </li>
<li>AppFolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) shares moved upwards by 16.59% to $311.75. The market value of their outstanding shares is at $9.6 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) stock increased by 10.48% to $2.27. The company's market cap stands at $58.3 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>MultiSensor AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) stock moved upwards by 9.95% to $0.77. The company's market cap stands at $23.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) shares declined by 24.1% to $3.11 during Friday's regular session. The company's market cap stands at $147.8 million. The company's, Q2 earnings came out yesterday. </li>
<li>AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) shares decreased by 19.49% to $2.91. The company's market cap stands at $69.4 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) shares declined by 17.44% to $15.39. The company's market cap stands at $1.0 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) stock fell 16.97% to $11.13. The company's market cap stands at $4.6 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) stock decreased by 16.55% to $1.16. The company's market cap stands at $17.2 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock fell 15.88% to $4.98. The company's market cap stands at $139.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEVA

APPF

BNZI

LIDR

MGRT

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

RIOT

UPLD

VRME

12 Information Technology Stocks Moving In Friday's Intraday Session

<a href="https://www.bloomberg.com/news/articles/2025-08-01/blackstone-tells-employees-they-can-return-to-nyc-office-aug-4" title="https://www.bloomberg.com/news/articles/2025-08-01/blackstone-tells-employees-they-can-return-to-nyc-office-aug-4">https://www.bloomberg.com/news/articles/2025-08-01/blackstone-tells-employees-they-can-return-to-nyc-office-aug-4</a>

Management

'Blackstone Tells Employees They Can Return to NYC Office Aug. 4' - Bloomberg News

JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) is set to give its latest quarterly earnings report on Monday, 2025-08-04. Here's what investors need to know before the announcement.
Analysts estimate that JBT Marel will report an earnings per share (EPS) of $1.28. 
JBT Marel bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.13, which was followed by a 2.31% increase in the share price the next day.
Here's a look at JBT Marel's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.84</td>
<td>1.82</td>
<td>1.4</td>
<td>1.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.97</td>
<td>1.70</td>
<td>1.5</td>
<td>1.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>15.0%</td>
<td>18.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754067906_0.png" alt="eps graph" />
<h3>JBT Marel Share Price Analysis</h3>
Shares of JBT Marel were trading at $137.8 as of July 31. Over the last 52-week period, shares are up 47.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/JBTM/earnings">To track all earnings releases for JBT Marel visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

JBTM

Insights Ahead: JBT Marel's Quarterly Earnings

BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) is gearing up to announce its quarterly earnings on Monday, 2025-08-04. Here's a quick overview of what investors should know before the release.
Analysts are estimating that BellRing Brands will report an earnings per share (EPS) of $0.50.
The market awaits BellRing Brands's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.00, leading to a 18.97% drop in the share price on the subsequent day.
Here's a look at BellRing Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.53</td>
<td>0.48</td>
<td>0.50</td>
<td>0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.53</td>
<td>0.58</td>
<td>0.51</td>
<td>0.54</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-19.0%</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754067869_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of BellRing Brands were trading at $54.58 as of July 31. Over the last 52-week period, shares are up 10.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BRBR/earnings">To track all earnings releases for BellRing Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRBR

Earnings Outlook For BellRing Brands

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) is preparing to release its quarterly earnings on Monday, 2025-08-04. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Axsome Therapeutics to report an earnings per share (EPS) of $-1.06.
Anticipation surrounds Axsome Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.67, leading to a 3.72% drop in the share price the following trading session.
Here's a look at Axsome Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.35</td>
<td>-0.99</td>
<td>-1.41</td>
<td>-1.33</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.68</td>
<td>-0.80</td>
<td>-0.49</td>
<td>-1.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754067855_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Axsome Therapeutics were trading at $101.38 as of July 31. Over the last 52-week period, shares are up 23.66%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Axsome Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Axsome Therapeutics.
Analysts have provided Axsome Therapeutics with 9 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $175.33, suggesting a potential 72.94% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Elanco Animal Health, Jazz Pharmaceuticals and Corcept Therapeutics, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Elanco Animal Health, with an average 1-year price target of $16.8, suggesting a potential 83.43% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Jazz Pharmaceuticals, with an average 1-year price target of $176.12, suggesting a potential 73.72% upside.</li>
<li>Analysts currently favor an Buy trajectory for Corcept Therapeutics, with an average 1-year price target of $134.33, suggesting a potential 32.5% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Elanco Animal Health, Jazz Pharmaceuticals and Corcept Therapeutics, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axsome Therapeutics</td>
<td>Outperform</td>
<td>61.95%</td>
<td>$111.67M</td>
<td>-107.81%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Buy</td>
<td>-1.00%</td>
<td>$684M</td>
<td>1.08%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>Outperform</td>
<td>-0.46%</td>
<td>$793.22M</td>
<td>-2.24%</td>
</tr>
<tr>
<td>Corcept Therapeutics</td>
<td>Buy</td>
<td>7.09%</td>
<td>$154.81M</td>
<td>2.98%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Axsome Therapeutics ranks at the top for Revenue Growth and Gross Profit, while it ranks at the bottom for Return on Equity among its peers.
<h3>Discovering Axsome Therapeutics: A Closer Look</h3>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Axsome Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 61.95%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -48.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -107.81%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Axsome Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.2%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.97, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<a href="https://www.benzinga.com/quote/AXSM/earnings">To track all earnings releases for Axsome Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXSM

A Look at Axsome Therapeutics's Upcoming Earnings Report

Transocean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) is gearing up to announce its quarterly earnings on Monday, 2025-08-04. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Transocean will report an earnings per share (EPS) of $-0.02.
The announcement from Transocean is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.01, leading to a 4.76% drop in the share price on the subsequent day.
Here's a look at Transocean's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.09</td>
<td>0</td>
<td>-0.04</td>
<td>-0.10</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.10</td>
<td>-0.09</td>
<td>0</td>
<td>-0.15</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>1.0%</td>
<td>9.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754067843_0.png" alt="eps graph" />
<h3>Tracking Transocean's Stock Performance</h3>
Shares of Transocean were trading at $2.92 as of July 31. Over the last 52-week period, shares are down 44.12%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/RIG/earnings">To track all earnings releases for Transocean visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Transocean

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count -5 To 410; U.S. Baker Hughes NatGas Rig Count +2 To 124; U.S. Baker Hughes Total Rig Count 540 Vs 542 Prior

WIIM

ICFI

ICF International shares are trading higher after the company announced better-than-expected Q2 adjusted EPS results and raised its FY25 Adjusted EPS guidance and GAAP EPS guidance.

National Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSA#NYSE">NSA</a>) is set to give its latest quarterly earnings report on Monday, 2025-08-04. Here's what investors need to know before the announcement.
Analysts estimate that National Storage will report an earnings per share (EPS) of $0.35. 
Anticipation surrounds National Storage's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.02, leading to a 4.76% drop in the share price the following trading session.
Here's a look at National Storage's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.56</td>
<td>0.58</td>
<td>0.60</td>
<td>0.63</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.54</td>
<td>0.60</td>
<td>0.62</td>
<td>0.62</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754067794_0.png" alt="eps graph" />
<h3>Tracking National Storage's Stock Performance</h3>
Shares of National Storage were trading at $29.46 as of July 31. Over the last 52-week period, shares are down 30.31%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Opinions on National Storage</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on National Storage.
National Storage has received a total of 2 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $36.0, the consensus suggests a potential 22.2% upside.
<h3>Peer Ratings Comparison</h3>
The below comparison of the analyst ratings and average 1-year price targets of Smartstop Self Storage, CubeSmart and Extra Space Storage, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Smartstop Self Storage, with an average 1-year price target of $41.33, suggesting a potential 40.29% upside.</li>
<li>Analysts currently favor an Neutral trajectory for CubeSmart, with an average 1-year price target of $47.17, suggesting a potential 60.12% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Extra Space Storage, with an average 1-year price target of $147.86, suggesting a potential 401.9% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Smartstop Self Storage, CubeSmart and Extra Space Storage, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Storage</td>
<td>Neutral</td>
<td>-3.97%</td>
<td>$133.25M</td>
<td>1.10%</td>
</tr>
<tr>
<td>Smartstop Self Storage</td>
<td>Outperform</td>
<td>14.74%</td>
<td>$41.98M</td>
<td>-2.22%</td>
</tr>
<tr>
<td>CubeSmart</td>
<td>Neutral</td>
<td>4.45%</td>
<td>$190.10M</td>
<td>3.12%</td>
</tr>
<tr>
<td>Extra Space Storage</td>
<td>Neutral</td>
<td>2.64%</td>
<td>$579.30M</td>
<td>1.80%</td>
</tr>
</tbody>
</table>

Key Takeaway:
National Storage is positioned at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity.
<h3>Unveiling the Story Behind National Storage</h3>
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, RightSpace, Northwest and Move It brands.
<h3>Understanding the Numbers: National Storage's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining National Storage's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -3.97% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: National Storage's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): National Storage's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.15%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 4.98, National Storage faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/NSA/earnings">To track all earnings releases for National Storage visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: National Storage's Earnings Preview

MSA Safety (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSA#NYSE">MSA</a>) is set to give its latest quarterly earnings report on Monday, 2025-08-04. Here's what investors need to know before the announcement.
Analysts estimate that MSA Safety will report an earnings per share (EPS) of $1.76. 
Investors in MSA Safety are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.10, which was followed by a 2.05% increase in the share price the next day.
Here's a look at MSA Safety's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.58</td>
<td>2.26</td>
<td>1.80</td>
<td>1.96</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.68</td>
<td>2.25</td>
<td>1.83</td>
<td>2.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754067786_0.png" alt="eps graph" />
<h3>MSA Safety Share Price Analysis</h3>
Shares of MSA Safety were trading at $177.87 as of July 31. Over the last 52-week period, shares are up 0.24%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on MSA Safety</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MSA Safety.
Analysts have provided MSA Safety with 3 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $189.33, suggesting a potential 6.44% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of HNI, Interface and ACCO Brands, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for HNI, with an average 1-year price target of $70.0, suggesting a potential 60.65% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Interface, with an average 1-year price target of $30.0, suggesting a potential 83.13% downside.</li>
<li>Analysts currently favor an Outperform trajectory for ACCO Brands, with an average 1-year price target of $6.0, suggesting a potential 96.63% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for HNI, Interface and ACCO Brands, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSA Safety</td>
<td>Buy</td>
<td>1.94%</td>
<td>$193.40M</td>
<td>5.12%</td>
</tr>
<tr>
<td>HNI</td>
<td>Buy</td>
<td>6.96%</td>
<td>$286.20M</td>
<td>5.97%</td>
</tr>
<tr>
<td>Interface</td>
<td>Outperform</td>
<td>2.65%</td>
<td>$110.96M</td>
<td>2.59%</td>
</tr>
<tr>
<td>ACCO Brands</td>
<td>Outperform</td>
<td>-11.56%</td>
<td>$99.60M</td>
<td>-2.18%</td>
</tr>
</tbody>
</table>

Key Takeaway:
MSA Safety ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus rating. However, it ranks at the bottom for Return on Equity.
<h3>Discovering MSA Safety: A Closer Look</h3>
MSA Safety Inc makes safety products that are used to protect workers in the oil and gas and mining industries. The products include breathing apparatuses, fall protection, portable gas detection systems, industrial head protection, fire and rescue helmets, and fixed gas and flame detection systems. End markets include the fire service, contractor, industrial, mining, oil and gas, and utilities industries. The company's reportable geographic segments are Northern North America; Latin America; Europe, Middle East &amp; Africa; and Asia Pacific. The company's operating segments have been aggregated into three reportable segments: Americas, International, and Corporate. Geographically the company generates the majority of its revenue from the United States.
<h3>MSA Safety's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: MSA Safety displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.94%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: MSA Safety's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.14%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): MSA Safety's ROE excels beyond industry benchmarks, reaching 5.12%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): MSA Safety's ROA stands out, surpassing industry averages. With an impressive ROA of 2.68%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: MSA Safety's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.46.
<a href="https://www.benzinga.com/quote/MSA/earnings">To track all earnings releases for MSA Safety visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For MSA Safety

The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years of age and older with hemophilia <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">A or B without inhibitors</a>.
In December 2024, the FDA <a target="_blank" href="https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915084" rel="noreferrer noopener">approved</a> Alhemo for patients 12 years of age and older with hemophilia A or B with inhibitors.
Currently, many hemophilia A or B treatments without inhibitors are administered via intravenous infusions. With this approval, Alhemo now offers a subcutaneous injection treatment option for this population.
Alhemo is designed to block a protein called tissue factor pathway inhibitor (TFPI), which stops blood from clotting.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/46123159/pfizer-seeks-label-expansion-for-hemophilia-drug-after-promising-data" target="_blank" rel="noreferrer noopener">Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data</a>
By inhibiting TFPI, Alhemo improves the production of thrombin, which helps to clot the blood and prevent bleeding, when clotting factors VIII and IX are missing or deficient, regardless of inhibitor status.
The primary <a target="_blank" href="https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916409" rel="noreferrer noopener">objective</a> of the pivotal phase 3 explorer8 trial was to compare the number of treated spontaneous and traumatic bleeding episodes, as measured by the ABR, in patients aged 12 years and older with HA/HB without inhibitors, receiving Alhemo prophylaxis versus no prophylaxis (on demand Factor VIII/Factor IX treatment).
The study showed a statistically significant reduction in ABR of 79% for hemophilia B patients and 86% for hemophilia A patients.
Additionally, notable reductions in the average and median ABRs further reinforced the efficacy of Alhemo prophylaxis in reducing bleeds across both patient groups, with an average ABR of 3.1 and a median ABR of 1.6 for hemophilia B patients, compared to 14.8 and 14.9, respectively, and an average ABR of 2.7 and median ABR of 2.9 for hemophilia A patients, compared to 19.3 and 19.6, respectively.
Alhemo is provided in prefilled, premixed pens for subcutaneous injection (60 mg/1.5 mL, 150 mg/1.5 mL, or 300 mg/3 mL) via thin 32 gauge, 4 mm needles, which are provided separately, offering an additional treatment choice for patients with hemophilia with inhibitors, and now without inhibitors.
In February, Novo Nordisk reported interim results from the phase 3 FRONTIER3 trial of 70 children (aged one-11 years old) with hemophilia A <a href="https://www.benzinga.com/general/biotech/25/02/43557877/novo-nordisk-eyes-2025-regulatory-filing-for-hemophilia-candidate-after-encouraging-pediatric-study-data" target="_blank" rel="noreferrer noopener">with and without inhibitors</a>.
The median ABR was zero; 74.3% of participants had zero treated bleeds.
All children with hemophilia A with inhibitors (n=14) reported zero treated bleeds. The data showed that Mim8 was well-tolerated and efficacious.
The company expects Mim8 regulatory submission during 2025.
In March this year, the FDA approved Sanofi SA's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with hemophilia A or B with or without <a target="_blank" href="https://www.benzinga.com/25/03/44560065/fda-approves-sanofis-hemophilia-drug" rel="noreferrer noopener">factor VIII or IX inhibitors</a>.
NVO Price Action: NVO stock is up 1.91% at $47.97 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46797786/reddit-q2-revenue-jumps-analysts-remain-cautious-despite-surge" target="_blank" rel="noreferrer noopener">Reddit Q2 Revenue Jumps 78%—Analysts Remain Cautious Despite The Surge</a></li>
</ul>
Photo: JHVEPhoto via Shutterstock.com

Biotech

Large Cap

Health Care

General

Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients

Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) is set to give its latest quarterly earnings report on Monday, 2025-08-04. Here's what investors need to know before the announcement.
Analysts estimate that Crescent Energy will report an earnings per share (EPS) of $0.28. 
The announcement from Crescent Energy is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.12 in the last quarter, leading to a 3.4% drop in the share price on the following day.
Here's a look at Crescent Energy's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.40</td>
<td>0.29</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.56</td>
<td>0.78</td>
<td>0.56</td>
<td>0.50</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754067737_0.png" alt="eps graph" />
<h3>Performance of Crescent Energy Shares</h3>
Shares of Crescent Energy were trading at $9.24 as of July 31. Over the last 52-week period, shares are down 12.51%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Insights on Crescent Energy</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Crescent Energy.
The consensus rating for Crescent Energy is Outperform, derived from 4 analyst ratings. An average one-year price target of $15.0 implies a potential 62.34% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Black Stone Minerals, Northern Oil &amp; Gas and Civitas Resources, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Black Stone Minerals, with an average 1-year price target of $14.0, suggesting a potential 51.52% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Northern Oil &amp; Gas, with an average 1-year price target of $33.25, suggesting a potential 259.85% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Civitas Resources, with an average 1-year price target of $42.88, suggesting a potential 364.07% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
In the peer analysis summary, key metrics for Black Stone Minerals, Northern Oil &amp; Gas and Civitas Resources are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crescent Energy</td>
<td>Outperform</td>
<td>44.52%</td>
<td>$788.58M</td>
<td>-0.07%</td>
</tr>
<tr>
<td>Black Stone Minerals</td>
<td>Neutral</td>
<td>-1.31%</td>
<td>$93.78M</td>
<td>0.78%</td>
</tr>
<tr>
<td>Northern Oil &amp; Gas</td>
<td>Neutral</td>
<td>8.50%</td>
<td>$224.54M</td>
<td>5.89%</td>
</tr>
<tr>
<td>Civitas Resources</td>
<td>Neutral</td>
<td>-10.24%</td>
<td>$472M</td>
<td>2.79%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Crescent Energy ranks at the top for Revenue Growth with 44.52%, outperforming its peers. However, it has the lowest Gross Profit at $788.58M and the lowest Return on Equity at -0.07%.
<h3>All You Need to Know About Crescent Energy</h3>
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
<h3>Key Indicators: Crescent Energy's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Crescent Energy showcased positive performance, achieving a revenue growth rate of 44.52% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Crescent Energy's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -0.23%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.07%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Crescent Energy's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Crescent Energy's debt-to-equity ratio surpasses industry norms, standing at 1.13. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/CRGY/earnings">To track all earnings releases for Crescent Energy visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRGY

Crescent Energy Earnings Preview

Boise Cascade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCC#NYSE">BCC</a>) is set to give its latest quarterly earnings report on Monday, 2025-08-04. Here's what investors need to know before the announcement.
Analysts estimate that Boise Cascade will report an earnings per share (EPS) of $1.72. 
Boise Cascade bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.22, leading to a 5.4% drop in the share price on the subsequent day.
Here's a look at Boise Cascade's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.28</td>
<td>1.84</td>
<td>2.32</td>
<td>2.76</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.06</td>
<td>1.78</td>
<td>2.33</td>
<td>2.84</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-8.0%</td>
<td>3.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754067726_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Boise Cascade were trading at $83.81 as of July 31. Over the last 52-week period, shares are down 33.4%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analysts' Take on Boise Cascade</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Boise Cascade.
The consensus rating for Boise Cascade is Buy, derived from 3 analyst ratings. An average one-year price target of $104.33 implies a potential 24.48% upside.
<h3>Comparing Ratings with Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Herc Holdings, GMS and Xometry, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Herc Holdings, with an average 1-year price target of $139.0, suggesting a potential 65.85% upside.</li>
<li>Analysts currently favor an Neutral trajectory for GMS, with an average 1-year price target of $101.68, suggesting a potential 21.32% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Xometry, with an average 1-year price target of $32.6, suggesting a potential 61.1% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Herc Holdings, GMS and Xometry, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boise Cascade</td>
<td>Buy</td>
<td>-6.62%</td>
<td>$260.31M</td>
<td>1.89%</td>
</tr>
<tr>
<td>Herc Holdings</td>
<td>Buy</td>
<td>12.38%</td>
<td>$283M</td>
<td>-2.14%</td>
</tr>
<tr>
<td>GMS</td>
<td>Neutral</td>
<td>-5.61%</td>
<td>$416.24M</td>
<td>1.85%</td>
</tr>
<tr>
<td>Xometry</td>
<td>Neutral</td>
<td>23.05%</td>
<td>$56.33M</td>
<td>-4.83%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Boise Cascade ranks at the bottom for Revenue Growth among its peers. It is at the top for Gross Profit. For Return on Equity, it is in the middle compared to its peers.
<h3>Delving into Boise Cascade's Background</h3>
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.
<h3>Boise Cascade: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Boise Cascade's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -6.62%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Boise Cascade's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.63%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Boise Cascade's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.89%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Boise Cascade's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.18%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
<a href="https://www.benzinga.com/quote/BCC/earnings">To track all earnings releases for Boise Cascade visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Boise Cascade's Earnings Potential

MODG

Topgolf Callaway Brands shares are trading lower. The company announced its CEO Artie Starrs will resign.

Press Releases

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Rapport Therapeutics to Host 2025 Investor and Analyst Day

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

Comments

Rapport Therapeutics

Intérêt court

Rapport Therapeutics (NASDAQ:RAPP) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL